<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01396226</url>
  </required_header>
  <id_info>
    <org_study_id>D4120C00002</org_study_id>
    <secondary_id>2011-001716-59</secondary_id>
    <nct_id>NCT01396226</nct_id>
  </id_info>
  <brief_title>A Multi-centre Study Comparing the Effects of AZD2927 and Placebo on the Electrical Activity in the Heart in Patients</brief_title>
  <official_title>A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Medical Products Agency
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess
           the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of
           AZD2927 in Patients Undergoing an Invasive Electrophysiological Procedure.

        -  The study has an adaptive design. In the 1st dose group the planned number of randomised
           patients is 24. The tentative number of randomised patients in the optional 2nd dose
           group is 12, 24 or 36 and thus a total maximum of 60 patients will be randomised in the
           study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Atrial Effective Refractory Period</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventricular Effective Refractory Period</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change in VERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paced QT Interval</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change in CS Paced QT interval (P600 MS) from before and after IP infusion during electrophysiological measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrio-ventricular Effective Refractory Period</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change from observation before IP infusion to during 1st and 2nd LAERP Mean</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PA Interval</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Reflects intra-atrial conduction and is defined as the interval from the onset of the P wave in the surface ECG to the onset of atrial activation (A) in the His bundle electrogram. Change from observation before IP infusion to 30 min after IP start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AH Interval</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change from observation before IP infusion to 30 mins after IP start. AH interval- the conduction time from the low right atrium at the inter-atrial septum through the AV node to the His bundle, ie, intra-nodal conduction time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HV Interval</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change from observation before IP infusion to 30 mins after IP start. HV interval - represents conduction time from the proximal His bundle to the ventricular myocardium, ie, infra-nodal conduction time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR Interval</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Interval from the onset of the P-wave to the start of the QRS complex. Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS Duration</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR Interval</measure>
    <time_frame>Baseline to last assessment during IP infusion</time_frame>
    <description>Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of AZD2927 administered as an iv infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo administered as an iv infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2927</intervention_name>
    <description>A single dose of AZD2927 administered as an iv infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single dose of placebo administered as an iv infusion</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or postmenopausal female, aged 20 to 80 years inclusive,

          -  clinical indication for catheter ablation of atrial flutter,

          -  history of paroxysmal atrial flutter, with or without paroxysmal AF. Single episodes
             of persistent atrial flutter or AF requiring cardioversion do not exclude the patient
             from the study,

          -  sinus rhythm at randomisation,

          -  adequate anticoagulation or antithrombotic treatment according to ESC guidelines 2010
             or national guideline,

        Exclusion Criteria:

          -  cardioversion within 14 days before randomisation,

          -  history of stroke or transient ischaemic attack (TIA). History of significant head
             trauma, epilepsy or other disorders increasing the risk for seizures,

          -  QTcF &gt;450 ms or &lt;350 ms measured in sinus rhythm at randomisation,

          -  history and/or signs of clinically significant sinus node dysfunction. Sinus
             bradycardia (50 beats per minute or less) at randomisation,

          -  personal or family history of Torsades de Pointes (TdP), any other polymorphic
             ventricular tachycardia, long QT syndrome, short QT syndrome, Brugada syndrome, or
             personal history of sustained (&gt;30 s) monomorphic ventricular tachycardia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan C Carlsson, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hakan Walfridsson, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Linkoping Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <results_first_submitted>September 24, 2012</results_first_submitted>
  <results_first_submitted_qc>September 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2012</results_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial refractoriness</keyword>
  <keyword>cardiac electrophysiology</keyword>
  <keyword>IKACh</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study had enrolled 20 patients. A total of 18 patients were randomised of which 12 patients received AZD2927. All patients who received treatment completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD2927</title>
          <description>AZD2927 solution for infusion</description>
        </group>
        <group group_id="P2">
          <title>PLACEBO</title>
          <description>Placebo solution for infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Who Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Who Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD2927</title>
          <description>AZD2927 solution for infusion</description>
        </group>
        <group group_id="B2">
          <title>PLACEBO</title>
          <description>Placebo solution for infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.9" spread="7.7"/>
                    <measurement group_id="B2" value="63.8" spread="8.3"/>
                    <measurement group_id="B3" value="59.9" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Atrial Effective Refractory Period</title>
        <description>Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>Full A analysis Set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Effective Refractory Period</title>
          <description>Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
          <population>Full A analysis Set (FAS)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="8.9"/>
                    <measurement group_id="O2" value="5" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="9.7"/>
                    <measurement group_id="O2" value="10.8" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Effective Refractory Period</title>
        <description>Change in VERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Effective Refractory Period</title>
          <description>Change in VERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="9"/>
                    <measurement group_id="O2" value="1.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paced QT Interval</title>
        <description>Change in CS Paced QT interval (P600 MS) from before and after IP infusion during electrophysiological measurements</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Paced QT Interval</title>
          <description>Change in CS Paced QT interval (P600 MS) from before and after IP infusion during electrophysiological measurements</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="8.7"/>
                    <measurement group_id="O2" value="6.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Atrio-ventricular Effective Refractory Period</title>
        <description>Change from observation before IP infusion to during 1st and 2nd LAERP Mean</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Atrio-ventricular Effective Refractory Period</title>
          <description>Change from observation before IP infusion to during 1st and 2nd LAERP Mean</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During IP 1st LAERP Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" spread="18.1"/>
                    <measurement group_id="O2" value="1.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During IP 2nd LAERP Mean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" spread="17.6"/>
                    <measurement group_id="O2" value="3.2" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PA Interval</title>
        <description>Reflects intra-atrial conduction and is defined as the interval from the onset of the P wave in the surface ECG to the onset of atrial activation (A) in the His bundle electrogram. Change from observation before IP infusion to 30 min after IP start</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>PA Interval</title>
          <description>Reflects intra-atrial conduction and is defined as the interval from the onset of the P wave in the surface ECG to the onset of atrial activation (A) in the His bundle electrogram. Change from observation before IP infusion to 30 min after IP start</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="12"/>
                    <measurement group_id="O2" value="9.3" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AH Interval</title>
        <description>Change from observation before IP infusion to 30 mins after IP start. AH interval- the conduction time from the low right atrium at the inter-atrial septum through the AV node to the His bundle, ie, intra-nodal conduction time.</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>AH Interval</title>
          <description>Change from observation before IP infusion to 30 mins after IP start. AH interval- the conduction time from the low right atrium at the inter-atrial septum through the AV node to the His bundle, ie, intra-nodal conduction time.</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="14.2"/>
                    <measurement group_id="O2" value="-2.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HV Interval</title>
        <description>Change from observation before IP infusion to 30 mins after IP start. HV interval - represents conduction time from the proximal His bundle to the ventricular myocardium, ie, infra-nodal conduction time.</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>HV Interval</title>
          <description>Change from observation before IP infusion to 30 mins after IP start. HV interval - represents conduction time from the proximal His bundle to the ventricular myocardium, ie, infra-nodal conduction time.</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="8.9"/>
                    <measurement group_id="O2" value="3.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PR Interval</title>
        <description>Interval from the onset of the P-wave to the start of the QRS complex. Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>PR Interval</title>
          <description>Interval from the onset of the P-wave to the start of the QRS complex. Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>06:00-08:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="17.0"/>
                    <measurement group_id="O2" value="19.3" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20:00-24:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="18.6"/>
                    <measurement group_id="O2" value="4.3" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QRS Duration</title>
        <description>Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>QRS Duration</title>
          <description>Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>06:00-08:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="6.1"/>
                    <measurement group_id="O2" value="-0.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20:00-24:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="9.6"/>
                    <measurement group_id="O2" value="-2.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RR Interval</title>
        <description>Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>RR Interval</title>
          <description>Change from observation before IP infusion to 6 to 8 hours and 20 to 24 hours after IP infusion</description>
          <population>FAS</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>06:00-08:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="170.4"/>
                    <measurement group_id="O2" value="57.2" spread="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20:00-24:00</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="202"/>
                    <measurement group_id="O2" value="-8.3" spread="139.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Atrial Effective Refractory Period</title>
        <description>Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>Per Protocol (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Left Atrial Effective Refractory Period</title>
          <description>Change in LAERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
          <population>Per Protocol (PP)</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="9.3"/>
                    <measurement group_id="O2" value="5" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Assessment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="10.1"/>
                    <measurement group_id="O2" value="10.8" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Effective Refractory Period</title>
        <description>Change in VERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Effective Refractory Period</title>
          <description>Change in VERP from before IP infusion to 1st and 2nd assessments during IP infusion</description>
          <population>PP</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="9.4"/>
                    <measurement group_id="O2" value="1.7" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Paced QT Interval</title>
        <description>Change in CS Paced QT interval (P600 MS) from before and after IP infusion during electrophysiological measurements</description>
        <time_frame>Baseline to last assessment during IP infusion</time_frame>
        <population>PP</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD2927</title>
            <description>AZD2927 solution for intravenous (i.v.) infusion</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - PLACEBO</title>
            <description>Placebo solution for intravenous (i.v.) infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Paced QT Interval</title>
          <description>Change in CS Paced QT interval (P600 MS) from before and after IP infusion during electrophysiological measurements</description>
          <population>PP</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="9.1"/>
                    <measurement group_id="O2" value="6.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD2927</title>
          <description>AZD2927 solution for infusion</description>
        </group>
        <group group_id="E2">
          <title>PLACEBO</title>
          <description>Placebo solution for infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

